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Abstract 
Objectives 
The objectives of this systematic review are to evaluate firstly, all published data on 
baseline and annual progression rates of radiographic damage from all longitudinal 
observational cohorts, and secondly, the association of standard clinical and 
laboratory parameters with long-term radiographic joint damage. 
Methods 
A comprehensive search of the literature from 1975 to 2014, using PubMed, 
SCOPUS and Cochrane databases, identified a total of 28 studies that 
investigated long-term radiographic progression, and 41 studies investigating 
predictors of long-term radiographic progression. This was submitted and 
approved by PROSPERO in February 2014 (Registration Number: 
CRD42014007589). 
Results 
Meta-analysis indicated an overall baseline rate of 2.02%, and a yearly increase of 
1.08% of maximum damage. Stratified analysis found that baseline radiographic 
scores did not differ significantly between cohorts recruiting patient’s pre and 
post 1990 (2.01% vs. 2.03%; p>0.01), however the annual rate of progression was 
significantly reduced in the post 1990 cohorts (0.68% vs. 1.50%; p<0.05). High 
levels of acute phase markers, baseline radiographic damage, anti-CCP and 
Rheumatoid Factor positivity remain consistently predictive of long-term 
radiographic joint damage.  
Conclusions 
Critical changes in treatment practices over the last three decades are likely to 
explain the reduction in the long-term progression of structural joint damage.  
Acute phase markers and presence of Rheumatoid Factor/anti-CCP are strongly 
associated with increased radiographic progression. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Introduction 
Radiographic damage is an important outcome in observational studies and 
clinical trials in Rheumatoid Arthritis (RA). Chronic synovitis in RA results in 
irreversible bone and cartilage destruction(1). Erosions are indicators of failure to 
control the disease(2,3) that are associated with increased pain and functional 
disability(4,5). 
 
Previous systematic reviews have shown(5,6) 39-73% of early RA patients to 
develop one or more erosions in the first 5-years, with radiographic damage 
progressing at a constant rate for the first 20-years of the disease(5). Subsequent 
systematic reviews(4,7) concentrated on specific predictors (functional assessment 
and disease activity indices) and their relationship with radiological damage. 
However, to date no review has used quantitative analysis techniques, including 
meta-analysis, to investigate radiographic progression rates. 
 
As structural damage is irreversible(5,8), it would be advantageous to identify 
patients at higher risk of severe damage so their treatment could be tailored 
earlier on. Predictive modelling is a relevant statistical method to identify factors 
associated with primary RA outcomes(8,9). Previous studies have highlighted 
relationships between radiographic progression and functional disability(4) and 
disease activity (7). Other factors like anti-CCP antibodies and genetic factors 
have yet to be fully reviewed. 
 
In this systematic review we have evaluated published data on baseline and 
annual progression rates of radiographic damage from longitudinal observational 
cohorts, and defined their association with standard clinical and laboratory 
variables. To date, this is the first review to use appropriate meta-analysis 
techniques to evaluate both the baseline and annual progression rates of 
radiographic joint damage scores, as well as the predictive markers identified, for 
all long-term observation cohort studies. 
 
Methods 
A systematic review protocol was developed to ensure the objectives and aims 
where outlined from the outset. This was approved by PROSPERO in February 
2014 (CRD42014007589) (PubMed Search in Supplementary Data 1). 
 
Identifying publications 
Publications were identified by computerised searches of PubMed, Cochrane 
Library (incl CENTRAL, CDSR, DARE, HTA) and Scopus. Additional lateral search 
techniques included checking reference lists, performing key word searches in 
Google Scholar and using the ‘cited by’ option in PubMed. Databases were 
searched from January 1st 1975 to February 31st 2014. The search strategy used 
key words and MeSH terms on the title/abstract and full text as appropriate.  
 
Inclusion/exclusion criteria 
Inclusion criteria to select publications comprised of: (1) investigated the 
progression or predictive/prognostic markers of radiographic joint damage, (2) 
patients had a diagnosis of RA, using validated classification criteria like the 
European League Against Rheumatology (EULAR) and/or the American College of 
Rheumatology (ACR) criteria, (3) baseline assessments occurred no later than 3-
years from symptom onset, (4) prospective cohort study design, (5) radiographic 
follow-up data available for at least 5-years for progression rates, and 3-years for 
predictive markers, (6) used Larsen or Sharp van der Heijde method (SvdH) to 
score radiographic damage, and (7) only publications in English. 
 
Publication screening 
One reviewer (LC) screened titles/abstracts identified in searches, using the 
selection criteria to identify potentially relevant papers. A second reviewer (EN) 
independently screened the full text of 10% of all publications identified against 
agreed inclusion criteria. Agreement was achieved in 97% with disagreements 
resolved through discussion. Supplementary Figure 1 shows publications 
identified, screened and included in this review. 
 Data extraction 
Two reviewers (LC and RS) extracted data using a pre-designed form, piloted to 
ensure all data necessary was captured. It included: cohort name, country of 
study population, scoring method used, number of patients included, years of 
recruitment, length of follow-up, sex, mean age, baseline DAS and HAQ scores, 
proportion of patients on DMARDS, proportion RF positive, number, 
mean/median and standard deviation/interquartile range of radiographic scores 
at each follow-up visit, analysis method used, significant and non-significant 
predictors identified the effect estimate and 95% confidence intervals. In cases 
where the raw data were not given in the published paper, the author was 
contacted to provide this data (n=21). 
 
Quality Assessment 
Studies were rated using the Downs and Blacks instrument for non-randomised 
studies of health care interventions(10). Since the studies did not examine clinical 
effectiveness, checklist items related to comparative groups (e.g. randomisation 
and blinding procedures) were omitted. One reviewer (LC) scored all studies using 
the amended checklist and another reviewer (RS) independently scored 10% of 
studies drawn at random. Discrepancies between reviewers were discussed and 
consensus achieved. 
 
Analysis 
Means and standard deviations of the Larsen or Sharp score were recorded at 
each follow-up time for each study. In cases where only a median score was 
obtained, the median and range was converted into a mean score and standard 
deviation(11). To estimate annual rates of change, with standard errors, a linear 
regression model was conducted with follow-up year as the independent variable. 
Baseline scores and annuals progression rates, with respective standard errors, 
where transformed into percentage maximum damage for each scoring method 
(12,13). Transformed scores were entered into random effects meta-analysis to 
calculate pooled effect estimates for both baseline radiographic scores and 
annual rate of change. 
 
To assess the strength of predictive markers, the regression coefficients and odds 
ratios (OR), with 95% confidence intervals, were collated. Unadjusted effect 
estimates was sought. Where these were not reported the adjusted estimates 
were used. Random effects meta-analysis was used for all models due to the 
likely high level of heterogeneity between studies. Analysis used Stata (version 
13); significance was assumed at p<0.05. 
 
Heterogeneity 
The study entry criteria aimed to include studies as homogenous as possible to 
allow appropriate meta-analysis. Heterogeneity between studies was predicted a 
priori, mainly due to differences in when cohorts started and differences in 
scoring methods. The i-Squared statistic for each model was found to be 
consistently above 80%, and therefore random effects models were used 
throughout. To investigate possible sources of heterogeneity, scoring method and 
recruitment year were entered into meta-regression models and were the basis of 
two separate stratified analyses. Given the low level of studies included in the 
analysis, the ten studies were stratified into two recruitment period groups, 1965–
1989 and 1990–2000. This provided equal groupings for stratified analysis. In 
addition, this marked a change in the clinical management of RA, were from 1990 
the focus moved toward treat-to-target, with more intensive treatment within the 
first three months of disease. 
 
Narrative Synthesis of predictive factors 
Identified markers were recorded and counted to ascertain common associations 
with a separate count of significant predictors. Where possible, meta-analysis was 
used to assess the strength of predictive markers. However, for several predictive 
markers meta-analysis was not possible as too few studies reported results that 
could be pooled. When meta-analysis was inappropriate a narrative synthesis of 
the data was conducted. 
 
Results 
Meta-analysis of long-term radiographic progression 
Of the 28 studies identified, ten provided the necessary data for meta-
analysis(14–22) (Table 1). Patients were recruited from 1965-2000 and follow-up 
ranged from 5-20 years. The number of patients included with baseline 
radiographic data ranged from 73-1121. Four studies used Larsen; six used the 
SvdH scores. Five recruited patients from 1965-1989 and five from 1990-2000.  
 
Table 1. Summary of cohorts stratified by recruitment year 
 
Baseline radiographic score 
The first analysis examined baseline radiographic score across all studies. The 
overall rate of damage at baseline was estimated at 2.02% (95% CI 1.37-2.67) of 
maximum damage. The sub-group pooled estimate for Larsen score was 3.41% 
(95% CI 1.80-5.01) of maximum damage (6.82 units); the sub-group pooled 
estimate for the SvdH score was 1.20% (95% CI 0.60-1.80) of maximum damage 
(5.38 units). Studies recruiting patients between 1965-1989 had a sub-group 
pooled estimate of 2.01% (95% CI 1.14-2.89) of maximum damage; studies 
recruiting between 1990-2000 reported a sub-group pooled estimate of 2.03% 
(95% CI 1.05-3.01) of maximum damage (See Figure 1).  
 
Title: Baseline Radiographic Score Pre and Post 1990 
Caption: Figure 1. Forest plot of baseline radiographic scores stratified by 
recruitment periods 
 
Annual rate of change 
In the second analysis overall annual rate of change was estimated at 1.08% (95% 
CI 0.72-1.44) of maximum damage. The sub-group pooled estimate for Larsen 
score was 1.38% (95% CI 1.80-5.01) of maximum damage (2.76 units/year); the 
SvdH score was 1.20% (95% CI 0.88-1.88) of maximum damage (4.03 units/year). 
Studies recruiting patients between 1965-1989 patients had a sub-group pooled 
estimate of 1.50% (95% CI 1.08-1.92) of maximum damage; for 1990-2000 it was 
0.68% (95% CI 0.47-0.90) of maximum damage (Figure 2).  
 
Title: Annual Rate of Radiographic Progression Pre and Post 1990 
Caption: Figure 2. Forest plot of annual rates of change stratified by 
recruitment periods 
 
Meta-Regression 
The small sample size (10 studies) limited the power to conduct meta-regression 
models with an appropriate number of covariates; however, it was important to 
investigate possible factors influencing the overall effect estimate given the high 
levels of heterogeneity between studies (i-squared score ranging from 90.5%-
98.3%). 
 
The meta-regression indicated that there was a statistically non-significant 
difference for baseline progression rates between recruitment periods (p>0.1), but 
a statistically significant difference for annual progression rates between 
recruitment periods (p<0.05), whilst controlling for scoring method. The models 
indicated that differences between Larsen and SvdH scoring methods were not 
statistically significantly different for annual progression rates (p>0.1), suggesting 
relative increases in either scoring method was comparable. Scoring method was 
a statistically significant factor for baseline progression rates (p<0.05). 
 
Review of predictive markers of long-term radiographic damage 
Forty-one papers were identified that examined predictive markers of 
radiographic joint damage, representing 21 cohort studies. Although several 
papers were based on the same cohort data (Table 2), the analysis techniques 
used were sufficiently different from each other to allow their inclusion in the 
analysis. 
 
Table 2. Table of studies investigating predictors of radiographic progression 
 
Twenty-eight studies used the SvdH (23,15,24–26,19,27–30,21,31–46,1); 13 used 
the Larsen scoring method (47–49,20,50–58). Twenty-four of 41 studies examined 
radiographic damage at a single time point, whilst 17 investigated radiographic 
damage expressed as a change in score over two time points. Thirteen studies 
transformed radiographic scores into binary variables and 27 treated the 
radiographic score as a continuous score. One study treated the radiographic 
score as an ‘event’ in a ‘time-to-event’ analysis(53). Overall 12 different analysis 
methods were used (Table 2). 
 
Title: Number of Significant and Non-Significant Predictive Factors 
Caption: Figure 3. Number of significant and non-significant predictive 
factors 
 
Acute phase Markers 
Acute phase markers (ESR or CRP) were one of the most frequently reported 
covariates (See Figure 3). Fifteen studies included the ESR and 13 found it was a 
statistically significant predictor. Eleven studies included CRP and 10 found it was 
a statistically significant predictor. Although there was sufficient data to conduct a 
meta-analysis, large intra-study differences on how acute phase markers were 
evaluated made formal meta-analysis inappropriate. While studies assessed acute 
phase markers as continuous predictors; other used them as categorical 
predictors, either using pre-defined cut-points or using quartiles. This made direct 
comparison between the effect estimates unfeasible. 
 
Courvoisier et al.(15) reported increased ESR indicated over a three-fold increase 
risk of a radiological damage score above the median at 10 years. Similar effect 
estimates were seen in other studies using similar analysis techniques. An odds 
ratio (OR) of 2.7 (CIs not given) was reported by Fex et al.(48) and an OR of 2.9 
(95% CI 1.01-5.88) was reported by Tanaka et al.(21). Similarly Bukhari et al.(23) 
reported an Incidence Rate Ratio (IRR) of 2.0 (95% CI 1.4-3.0). Using linear 
regression techniques, Lindqvist et al.(51) reported an average increase of 0.42 
(95% CI 0.62-1.04) units of the Larsen Score for every one-unit increase in CRP. 
Mustila et al.(52) reported only ESR was significantly associated with radiographic 
joint damage at 12, 36, 60 and 84-months in univariate analysis, whereas RF was 
only statistically significant at 36-months, and perinuclear Antineutrophil 
Cytoplasmic Antibodies (pANCA), Antikeratin Antibodies (AKA), Antiperinuclear 
Factor (APF) and Age were not associated at any time.  
 
Anti-Cyclic Protein Antibodies (ACPA) and Rheumatoid Factor (RF) 
ACPA, largely anti-CCP, was evaluated in 16 studies and 14 of these reported 
statistically significant associations. Using linear regression, Lindqvist et al.(51) 
reported patients positive for anti-CCP had on average an increase of 37 units on 
the Larsen score compared to anti-CCP negative patients over 10 years. Nyhäll-
Wåhlin et al.(30) reported an increase of 14.74 over 5 years. Anti-CCP positive 
patients were also reported to have between a 2.3 and 9.3 fold increase in risk of 
rapid radiological progression(24,25). 
 
The predictive role of RF was evaluated in 21 studies and 12 reported statistical 
significance. Four studies investigating radiographic progression based on low or 
high radiographic damage groups showed RF positive patients were 1.8-2.8 times 
more likely to have high rates of long-term radiographic joint 
damage(21,23,24,55). 
 
To assess the relative strength of anti-CCP and RF, studies reporting OR and 95% 
confidence intervals were entered into a random effects meta-analysis. Five out of 
the 13 studies reporting anti-CCP and 10/21 studies reporting RF were included 
in the meta-analysis. Reasons for exclusion comprised insufficient data, lack of 
data on measures of variation and no calculated ORs. The overall pooled effect 
estimate for anti-CCP was 2.49 (95% CI 1.96-3.15) and for RF was 2.07 (95% CI 
1.61-2.65) (Figure 4). These findings suggest a moderate difference between the 
two markers, with anti-CCP more strongly associated; but overlapping 95% CIs 
suggest this difference is statistically non-significant. All five studies included in 
the meta-analysis for anti-CCP showed an increased risk. Only one reported a 
statistically non-significant result, which was also the only adjusted effect estimate 
included (49). All but two studies included in the RF analysis reported an 
increased risk (28,49). 
 
Title: Forest Plot of Anti-CCP, RF and HLA-DRB1 
Caption: Figure 4 – Forest plot of Anti-CCP, RF and HLA-DRB1 
 
Genetic Factors 
Sixteen studies investigated the influence of genetic factors on radiographic 
progression and 12 reported statistically significant associations. Four studies 
used follow-up data of >=5years; 12 were restricted to 3-4years follow-up. ORs 
for the presence of HLA-DRB1-SE ranged between 1.31 and 2.6(23,24,34). Two 
studies by Constantin et al showed HLA-DRB1 was associated with increased 
radiographic progression over 4 years(35,36). 
 Seven of the 16 studies provided sufficient data for meta-analysis. A random 
effects model showed an overall pooled estimate of 1.53 (95% CI 1.09-2.14) 
(Figure 4). Two of the 7 studies reported a decreased risk (15,40). 
 
 
 
Other factors 
There was limited evidence that age and female sex predicted radiographic joint 
damage. Only 4/12 and 4/15 studies respectively reported statistically significant 
findings. The reported effect sizes of both age and sex were low: age gave 
1.14(24) to 1.2(23) times increase in risk, while female sex reduced risk by 25% 
(24). Few studies evaluated joint counts, Disease Activity Score, pANCA, MMP-3 
and functional disability making it impractical to draw conclusions about their 
impact on radiographic damage or to undertake meta-analyses. 
 
Quality Assessment 
All studies were assessed for quality using the Downs and Blacks Quality 
Assessment Checklist (10) (Supplementary Figure 2 and Supplementary Table 1). 
Most studies were of good quality. All studies reported clear aims, objectives and 
outcome measures and recruited representative patients. Only 3 studies (6%) 
reported on missing data and only 7 (15%) reported on losses to follow-up. The 
use of appropriate statistical methods was also lacking, particularly in the 3-5 
year follow-up predictive studies, where only 13 studies (27%) used appropriate 
statistical methods.  
 
Discussion 
This review is the first to use meta-analysis techniques to provide accurate 
estimates of overall radiographic damage at presentation and over a 20-year 
period in early RA patients. Data from 10 studies shows the overall radiographic 
damage rate at presentation was 2.02% of maximum damage, and the overall 
annual progression rate was 1.08% of maximum damage.  
 
Previous reports(5) estimated total annual radiographic progression rates were 
1.9% of maximum damage; the Larsen score progressed 3.8 units/year (2.5% 
maximum damage) and SvdH score progressed 4.3 units/year (1.3% maximum 
damage) over the first 15 years. The present study found similar rates with an 
overall progression rate of 1.08% (95% CI 0.72-1.44) of maximum damage. Split 
by scoring method, the Larsen score progressed 2.76 units/year (1.38% maximum 
damage), and the SvdH score progressed 4.03 units/year (1.20% maximum 
damage) over the first 20-years of disease. The differences in rates between our 
findings and previous reports (5) are likely to be multifaceted. Firstly, meta-
analytical techniques to calculate pooled effect estimates give different rates than 
relying on averages. Meta-analysis is a more robust method as larger studies are 
given a higher weighting, reducing the influence of less precise estimates from 
smaller studies; it also estimates precision (95% confidence intervals). Secondly, 
our inclusion criteria focussed on observational cohorts of early RA patients. This 
ensured a more homogenous study sample as patients in RCTs are highly 
selected with higher levels of disease activity and higher rates of radiographic 
progression(13,40). This review studied patients from ‘true-to-life’ clinical settings. 
 Stratifying studies by recruitment year showed annual progression rates in studies 
recruiting between 1990-2000 was more than half the rate reported in studies 
recruiting between 1965-1989. However, baseline radiographic damage was 
similar across both recruitment periods. The reduction in radiographic 
progression from 1965-2000 is concordant with data from Finckh et al (59), who 
found decreased progression rates from 1970-1990, and Sokka et al (54), who 
found decreased 5-year radiographic progression rates across three cohorts 
(1983-1985, 1988-1989 and 1995-1996). Finckh et al.(59) suggested this was a 
consequence of more intensive therapies as the temporal effect diminished after 
controlling for DMARD use. More recent data from RCTs show combinations of 
synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) and biologics are 
highly effective in slowing radiographic progression (60), particularly during the 
‘Window of Opportunity’(12). Reduced rates of radiographic progression was also 
seen in a systematic review of RCTs, where more recent RCTs of patients on 
methotrexate had less radiographic progression compared to RCTs conducted 
earlier(61).  
 Differences between the two recruitment periods in our review also coincides 
with changes in clinical management, particularly more intensive treatment in the 
1990s with methotrexate the anchor DMARD(62). Pincus et al.(62) reported that 
improvements in radiographic outcomes from 1985 to 2000 were associated with 
better joint scores, functional capacity and mortality outcomes. How much of 
these changes should be attributed to better treatment strategies however, 
remains uncertain due to the non-randomised study designs(54,62).  
 
Interestingly there is an apparent dearth of new large observational cohort 
studies of new unselected RA patients. One factor could be the development of 
national registers of patients treated with biologics, which diverted expertise away 
from other observational cohorts. Other factors include continuing recruitment to 
observational studies and less emphasis on collecting radiographic assessments. 
 
The predictive factors we identified is in agreement with previous findings(5) 
including the importance of acute phase markers and RF positivity. This review 
also found evidence for the association between anti-CCP positivity and long-
term radiological damage. Navarro-Compán et al (7) assessed the relationship 
between radiographic joint damage and Disease Activity Indices (DAI) like the 
Disease Activity Score (DAS). It would appear that while DAIs are clinically useful, 
the individual components of the DAI’s, particularly SJC and acute phase markers, 
were better predictors.  
 
Our review is the first to summarise associations of anti-CCP and genetic factors 
with radiographic progression in long-term cohort studies. De Rooy et al(24) 
found HLA-DRB1 shared epitopes increases the risk of radiographic joint damage 
at 5-years, but they did not include anti-CCP in their models. Recent 
studies(63,64) highlight the importance on the dependence of RA-related genetic 
markers on anti-CCP for associations with radiographic progression. Kaltenhauser 
et al.(49) reported that anti-CCP and DRB1*04 SE, used as a compound marker, 
was statistically significantly associated with increased radiographic damage at 4-
years. However, Kroot et al.(26) found anti-CCP but not HLA-DRB4 was 
statistically significantly associated in multivariate analysis. This evidence suggests 
an association between SE-positive alleles and anti-CCP antibodies, though the 
pathogenetic mechanisms remain unclear(49). Further study of specific HLA-DRB1 
haplotypes may show a prognostic role(63). Currently, genetic markers do not 
provide much additional prognostic information that can be applied clinically. 
 
Several studies included in our review(28,46,49) found RF was not a significant 
predictor in the presence of anti-CCP, suggesting anti-CCP is the superior marker 
of long-term radiographic damage. Our meta-analysis suggests that anti-CCP 
could be more highly associated with increased radiographic damage. However, 
differences in specific RF antibodies and titre levels may explain variations 
between studies. 
 
The heterogeneity of the methods and analysis techniques used meant it was 
impossible to conduct a formal meta-analysis on all predictive markers to allow a 
direct aggregation of these results. One challenge in comparing studies related to 
differences in study design(65). When investigating novel markers in the absence 
of multivariate methods, the importance of well-established factors like 
seropositivity and acute phase reactants may not be appropriately considered. 
Consequently the effect of novel markers may be masked, or over-exaggerated 
when already established factors are not considered (9). Novel markers like MMP-
3(25,53) have potentially strong associations with radiographic joint damage, but 
more evidence is needed with large patient samples using appropriate 
multivariate modelling techniques. 
 
Another limitation is that it was not possible to stratify patients using disease 
markers like seropositivity when modelling radiographic progression rates, since it 
would require more detailed and complex data from each cohort, which would be 
unfeasible to obtain. Consequently, although the review highlighted the potential 
differences in radiographic progression in patients with anti-CCP positivity, we 
could not produce separate rates of radiographic progression for seropositive 
and seronegative RA patients. Furthermore, the direct impact of treatment could 
not be fully assessed. Evaluating recruitment years provides a surrogate marker of 
changes in treatment practices, but we could not directly model the effect of 
treatment. Nevertheless, it is likely patients received standard contemporary care 
based on published guidelines about treatment regimens from the time they 
were being studied. 
 
We conclude the progression of radiographic damage has halved since 1990, with 
improved treatment providing the most likely cause. RF/anti-CCP, along with 
increased markers of acute phase reactants remain strongly associated with 
radiographic damage, however the value of other novel antibodies need further 
study. Finally, while the investigation of different haplotypes is proving hopeful, 
currently the genetic data is of limited additional prognostic value independent 
of anti-CCP positivity. 
 
Key Messages 
 
 Progression of radiographic damage in 2002-2011 is significantly lower 
compared to 1986-2001 in early RA  
 Acute phase markers and RF/anti-CCP positive RA remain important 
predictors of erosive disease in RA. 
 Longitudinal-studies needed on whether Anti-CCP is superior to RF in 
predicting radiographic damage in RA 
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